We are live on ! Find out more
NVRO

NEVRO CORP.

Delisted

NVRO was delisted on the 2nd of April, 2025.

129 hedge funds and large institutions have $134M invested in NEVRO CORP. in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 39

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

2% less funds holding

Funds holding: 131129 (-2)

36% less capital invested

Capital invested by funds: $210M → $134M (-$76.5M)

50% less call options, than puts

Call options by funds: $2.32M | Put options by funds: $4.61M

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
129
Holders Change
-2
Holders Change %
-1.53%
% of All Funds
1.7%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
26
Increased
47
Reduced
39
Closed
28
Calls
$2.32M
Puts
$4.61M
Net Calls
-$2.3M
Net Calls Change
+$5.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.23M -$649K -140,638 -30%
Charles Schwab
27
Charles Schwab
California
$1.17M +$49.9K +10,806 +4%
AQR Capital Management
28
AQR Capital Management
Connecticut
$1.15M +$672K +145,463 +88%
Renaissance Technologies
29
Renaissance Technologies
New York
$1.12M -$76.7K -16,610 -5%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$944K -$144K -31,200 -11%
TI
31
Trexquant Investment
Connecticut
$881K -$106K -22,856 -9%
Two Sigma Investments
32
Two Sigma Investments
New York
$816K +$289K +62,568 +40%
BCM
33
Bridgeway Capital Management
Texas
$787K -$164K -35,500 -14%
Prudential Financial
34
Prudential Financial
New Jersey
$728K +$640K +138,700 +243%
Lazard Asset Management
35
Lazard Asset Management
New York
$661K -$727K -157,523 -47%
UBS Group
36
UBS Group
Switzerland
$638K +$747K +161,836 +1,689%
Ameriprise
37
Ameriprise
Minnesota
$576K -$439 -95 -0.1%
Jane Street
38
Jane Street
New York
$555K +$163K +35,405 +31%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$518K +$179K +38,869 +39%
Bank of America
40
Bank of America
North Carolina
$507K -$655K -141,896 -51%
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$495K -$168K -36,442 -22%
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$484K -$171 -37 -0%
SFI
43
Susquehanna Fundamental Investments
Pennsylvania
$435K +$540K +116,996 New
EGM
44
Engineers Gate Manager
New York
$435K +$6.27K +1,358 +1%
MA
45
MYDA Advisors
New York
$432K +$536K +116,200 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$420K +$111K +23,994 +27%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$402K -$6.02K -1,305 -1%
Walleye Capital
48
Walleye Capital
New York
$378K -$476K -103,061 -50%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$338K -$205K -44,364 -33%
TCM
50
TD Capital Management
Tennessee
$315K

NVRO Hedge Fund Activity: Q4 2024 in Review

129 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q4 2024, worth a combined $134M — down 36% from $210M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of NVRO and 26 opened new positions — a net loss of 2 holders — while 39 trimmed existing stakes and 47 added.

The largest buyer was Shay Capital, adding an estimated $4.31M. The largest seller was Engaged Capital, exiting entirely with an estimated $13.7M sold.

  • 129 institutional investors held NEVRO CORP. (NVRO) as of Q4 2024, down from 131 in Q3 2024.
  • Funds reported $134M of NEVRO CORP. stock for Q4 2024, down 36% quarter-over-quarter.
  • 26 funds opened new NEVRO CORP. positions in Q4 2024 and 28 closed out, a net change of -2 holders.
  • The largest NEVRO CORP. buyer in Q4 2024 was Shay Capital, an estimated $4.31M added.
  • The largest NEVRO CORP. seller in Q4 2024 was Engaged Capital, an estimated $13.7M sold.

Based on aggregated 13F filings for Q4 2024.